Pneumococcal conjugate (PCV13) vaccine uses a carrier protein (CRM197) to provide biostable immunity in children below 2 years for pneumococcal disease. Biological E. Limited was able to make a vaccine that was new to the market using their in-house technology.
CRM197 production is carried out in fermentation with optimized media using C. diphtheriae C7 strain, which was engineered in-house to increase CRM197 yield. The fermenter broth containing CRM197 is further processed by downstream processing. The purified CRM197 is analyzed to meet the predetermined quality attributes.
Disclaimer:
Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.
Please enter your details
Please provide your name and email to continue. Your details are saved in this browser for future use.
Latest Updates
Loading…
⚠️
You are leaving this website
You are about to be redirected to an external website that is not operated by
India Science, Technology & Innovation (ISTI) Portal.
Quick Information
Acces sibility Controls